Industrifonden investerar 11 miljoner kronor i det svenska life science-bolaget Athera Biotechnologies, enligt ett pressmeddelande. Athera Biotechnologies AB

Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status

Clinical Trials; 648 Views. Last patient dosed in Athera’s Phase 2 study. Malin Otmani. April 2, 2020 Athera Biotechnologies announces that the About Athera Biotechnologies Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr där Industrifonden, Östersjöstiftelsen och Sciety-nätverket deltog. Det nya kapitalet ska användas för en klinisk fas 2-studie och bolaget siktar på ett förvärv från en större aktör efter att studien är genomförd.

The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020. 20 articles with Athera Biotechnologies. Athera raises 55 million SEK in new share issue. 5/21/2019. Biotech company Athera announce the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from the Sciety network of investors. Athera Receives FDA Orphan Drug Designation for PC-mAb in prevention of vascular access failure in kidney disease patients Athera Biotechnologies AB announced today that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end stage renal disease, who are preparing for or undergo hemodialysis Athera has an agreement with Richter-Helm BioLogics GmbH & Co. KG in Hamburg, Germany, for the process development of the product.

Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr där Industrifonden, Östersjöstiftelsen och Sciety-nätverket deltog. Det nya kapitalet ska användas för en klinisk fas 2-studie och bolaget siktar på ett förvärv från en större aktör efter att studien är genomförd.

ATH3G10 Styrelseledamot, Athera Biotechnologies AB. Styrelseledamot, Lipidor AB. Styrelseledamot, Nanexa AB. Styrelseledamot, Pharmor AB. Styrelseledamot, Isles of AstraZeneca AB, http://astrazeneca.se. Athera Biotechnologies AB, http://www.athera.se.

BiotecEra, Inc. is a biotechnology company (C-Corp) located in Athens, Georgia. We are dedicated in development and commercialization of innovative

PC is exposed in blood vessels in … Om Athera Biotechnologies AB. Athera Biotechnologies AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 1 anställd 2019. Antalet anställda är oförändrat sedan året innan. Bolaget är ett aktiebolag som varit aktivt sedan 2002. 2017-10-11 Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för Athera Biotechnologies AB Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. athera 23 athera biotechnologies 22 cardiovascular disease 18 therapeutic antibody 16 clinical 14 hjärtkärlsjukdom 14 läkemedel 14 clinical study 13 immunovascular disease 13 inflammation 11 Athera reports last patient visit for Phase 2 trial in STEMI patients Press releases • Jul 08, 2020 08:06 CEST.

Home · Athera Biotechnologies · Nyhetssvepet onsdag 4 juli. 4 juli, 2018.
Kazim ali

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease. Athera is a clinical stage biopharmaceutical Apr 2, 2020 Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic antibodies, announced that the last patient has been dosed Athera Biotechnologies is a clinical-stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular Phosphorylcholine fully human monoclonal antibody (PC-mAb), is being developed by Athera Biotechnologies, a part of the Karolinska Development portfolio With its lead candidate, ATH3G10, a first-in-class antibody indicated for large ST- elevation myocardial infarction (STEMI), Athera Biotechnologies is harnessing Feb 28, 2018 Athera Biotechnologies announces that a composition of matter patent covering antibodies with binding to phosphorylcholine, PC has been Sponsor: Athera Biotechnologies AB. Information provided by (Responsible Party ):.

Athera Biotechnologies AB har haft sitt nuvarande firmanamn sedan 2002-02-18. Aktiekapitalet är 8 269 700 kr. Check Athera Biotechnologies's profile on ExecLibrary, current management team, past employees information, social channels, interesting news for target accounts and … Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients.
Pråmen åhus öppettider

gamla instruktioner ikea
identifiera språk till svenska
bilverkstad fagersta
inaktivera windows update
körkort tappat bort

Pågående uppdrag: Styrelseordförande i Athera Biotechnologies AB. Styrelseledamot i Olsson Solutions AB, IRLAB Sweden, Gesynta Pharma AB, European Society of Cardiology och Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt- och lungsjukdomar. Aktieinnehav: 2 000 A-aktier.

1. Aktiekapital.